Get started
Author

Marlies De Bock

Observed names: Bock Marlies, De Bock M., Marlies De Bock
ORCID: 0000-0001-9439-9881
Observed ORCID: 0000-0001-9439-9881
OpenAlex ID: A5027844357
First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial
2024 · Christian Marth, Richard G. Moore, et al. · Journal of Clinical Oncology · 83
Psoriasis Vulgaris Exacerbation during Treatment with a PD-1 Checkpoint Inhibitor: Case Report and Literature Review
2018 · Marlies De Bock, Eva Hulstaert, et al. · Case Reports in Dermatology · 67
PDF
Pediatric speech-language pathology in East Africa: educational opportunities and availability of speech-language services
2022 · Cassandra Alighieri, Marlies De Bock, et al. · Logopedics Phoniatrics Vocology · 9
Optimal treatment duration in metastatic renal cell carcinoma patients responding to immune checkpoint inhibitors: should we treat beyond two years?
2025 · Alexander Decruyenaere, Gennigens Christine, et al. · Acta Oncologica · 8
PDF
Efficacy and toxicity of sorafenib in patients with adenoid cystic carcinoma of the head and neck: a case series of five patients
2019 · Karen Couvreur, Jacobs Celine, et al. · Acta Clinica Belgica · 6
Paraneoplastic Raynaud’s phenomenon as sign of progression: a case report on a patient with breast cancer
2020 · Tine Vanlancker, Barbara Stragier, et al. · Acta Clinica Belgica · 2
Sacituzumab tirumotecan versus treatment of physician's choice in previously treated endometrial cancer (TroFuse-005/ENGOT-en23/GOG-3095): a randomised, open-label, phase 3 trial
2026 · Domenica Lorusso, Jérôme Martin-Babau, et al. · The Lancet · 1
Asymptomatic hypercalcemia, caused by sarcoid-like granulomatosis, induced by checkpoint inhibition
2025 · Vandemaele N., Stragier B., et al. · Acta Clinica Belgica · 1
Works count: 8
Citation count: 177
H-index: 5
I10-index: 2
Year
Topic
Type